Urinary Sex Steroid Metabolites: Medication-Driven Changes Explained

A urinary sex steroid metabolite panel, sometimes ordered as a DUTCH (Dried Urine Test for Comprehensive Hormones) panel or a 24-hour urine steroid profile, measures how estrogen, progesterone, and androgens are broken down into downstream compounds rather than how much circulating hormone is present at one moment. It is a laboratory-developed test used mainly in functional and integrative medicine settings. It is not an FDA-approved diagnostic device, and no major endocrinology or oncology guideline currently recommends it as a routine screening or risk-stratification tool. That distinction matters because the number a patient sees on a report, such as a 2-OHE1 to 16α-OHE1 ratio, is frequently interpreted as if it were a validated clinical risk marker, when its clinical utility is still an area of active, unsettled research.

The single most important fact for interpreting any result on this panel is this: the same ratio value can mean something different depending on the medications and supplements a person is taking at the time of collection. Oral estrogen, aromatase inhibitors, tamoxifen, testosterone therapy, GLP-1 receptor agonists, and DIM supplements all shift metabolite concentrations or ratios through distinct, partly understood mechanisms, so a panel cannot be interpreted correctly without a current medication list.

What the test actually measures

Estrogen metabolism branches at several liver enzymes. CYP1A2 hydroxylates estrone and estradiol at the C-2 position, producing 2-OHE1 and 2-OHE2. CYP1B1 hydroxylates at C-4, producing 4-OHE1. A separate pathway produces 16α-OHE1, a metabolite with stronger estrogen-receptor binding activity than the 2-OH metabolites. Catechol-O-methyltransferase (COMT) then methylates 2-OHE1 into 2-methoxyestrone (2-MeOE1), a step that requires adequate methyl donor status (folate, B12, magnesium, SAMe). Progesterone is metabolized mainly to pregnanediol and allopregnanolone, and androgens to androsterone, etiocholanolone, and related compounds. This basic enzymology is well established in the pharmacology literature; it is the clinical meaning of specific ratio thresholds that remains far less settled.

What is established, what is plausible, and what is not established

Established: the enzymatic pathways above exist and are measurable in urine; oral estrogen undergoes first-pass hepatic metabolism in a way that transdermal estrogen does not; aromatase inhibitors sharply suppress total estrogen production and its downstream metabolites; adipose tissue is a major site of peripheral aromatization, so major weight change alters total estrogen metabolite output; DIM and indole-3-carbinol induce CYP1A2 activity.

Plausible but unproven at the level of individual patient care: that a specific 2-OHE1:16α-OHE1 ratio target (commonly cited as 2.0 or higher) predicts an individual's breast cancer risk, that correcting the ratio with supplements changes clinical outcomes, and that 4-OHE1 concentration on a commercial urine panel is a reliable proxy for DNA-adduct-mediated carcinogenesis risk in an individual patient. Observational cohort work from decades ago reported associations between estrogen metabolite ratios and breast cancer risk in some populations, but effect sizes, reproducibility across cohorts, and applicability to a single patient's urine test result have not been established well enough to guide individualized decisions. Anyone relying on a specific published relative-risk figure for this ratio should ask their ordering clinician to verify the study against current primary literature rather than accept a number carried over from marketing materials or older secondary sources.

Not established: that this panel should replace standard breast cancer risk assessment tools, that self-directed supplementation to shift the ratio prevents cancer, or that an "optimal" range validated in one commercial lab's population applies uniformly across ages, menopausal status, and ethnic groups.

Reference ranges are commercial, not regulatory

Ranges reported on DUTCH or 24-hour urine panels come from each lab's internal population data, not from a national reference standard. A commonly cited target is a 2-OHE1:16α-OHE1 ratio at or above roughly 2.0, with some functional-medicine practitioners using 2.5 to 3.5 as an "optimal" zone, and a preference for lower absolute 4-OHE1 and a 2-MeOE1:2-OHE1 ratio above roughly 0.3 to suggest adequate COMT methylation. These figures are consistent with what several commercial labs publish, but they have not been adopted as a diagnostic threshold by a professional endocrinology or oncology body, and absolute concentrations vary by menopausal status, body composition, and time of collection. Readers should treat published numeric ranges as lab-specific reporting conventions rather than validated medical cutoffs.

How specific medications change the picture

Oral versus transdermal estrogen

Oral estradiol passes through the liver before reaching systemic circulation, and this first-pass effect is understood to increase 16α-hydroxylation relative to 2-hydroxylation, which can lower the 2:16 ratio compared with the same dose given transdermally. Transdermal estradiol bypasses first-pass hepatic metabolism and is generally reported to have a smaller effect on this ratio. This directional difference is well supported by pharmacology, though exact percentage shifts vary between the small studies that have measured it, and any specific number quoted should be checked against the primary study before being used in a clinical conversation. The practical implication: a woman with a baseline 2:16 ratio near the low end of the reported range who needs estrogen therapy has a route-of-administration option worth discussing with her prescriber, and a panel drawn while she is on oral estrogen should not be compared directly to reference ranges built from women not taking oral estrogen.

Aromatase inhibitors (anastrozole, letrozole, exemestane)

Aromatase inhibitors block peripheral conversion of androgens to estrogens and are understood to reduce total urinary estrogen metabolites substantially in postmenopausal women, consistent with their known pharmacologic mechanism and their FDA-approved indication for hormone-receptor-positive breast cancer. Because both 2-OH and 16α-OH pathways are suppressed, the resulting ratio can look favorable even though absolute concentrations are near the assay's lower limit, where ratio math becomes statistically unstable. On aromatase inhibitor therapy, absolute metabolite values carry more clinical information than the ratio.

Tamoxifen and raloxifene

Tamoxifen and raloxifene are selective estrogen receptor modulators (SERMs) with FDA-approved indications in breast cancer risk reduction and treatment settings, distinct from any use in a urinary metabolite panel. Mechanistic and small clinical studies suggest tamoxifen may reduce CYP1B1-driven 4-OHE1 production, a proposed but not fully confirmed mechanism contributing to its anticancer effect. This should be described as a research hypothesis under active investigation, not an established metabolic effect that a specific patient can expect to see reproduced on their own panel.

Testosterone therapy in women (off-label in the United States)

Testosterone is not FDA-approved for female sexual dysfunction in the United States; when prescribed for hypoactive sexual desire disorder it is an off-label or compounded use, and this should be stated plainly to any patient considering it. Increasing the androgen substrate pool can increase peripheral aromatization to estradiol in women with residual ovarian or adrenal hormone production, which can raise downstream estrogen metabolites from a low baseline. In postmenopausal women with low endogenous androgen production, this is more likely to restore metabolite levels toward a premenopausal pattern than to push them above it, but individual response varies and has not been mapped precisely against ratio targets.

Testosterone replacement therapy in men

Men aromatize a portion of circulating testosterone to estradiol; raising total testosterone from a hypogonadal to a mid-normal range through FDA-approved testosterone replacement therapy is expected to raise total urinary estrogen metabolites as well, roughly in proportion to the testosterone dose and to individual aromatase activity, which is higher in men with greater adiposity. A man on TRT who has an elevated 4-OHE1 result should have his body composition assessed, since adipose tissue expresses CYP1B1 and channels a larger share of estrogen toward the 4-OH pathway; this is a physiologic explanation worth raising with a prescriber, not a confirmed diagnostic rule.

GLP-1 receptor agonists (semaglutide, tirzepatide)

Large randomized trials of semaglutide, including the STEP program, have demonstrated substantial mean body weight reduction compared with placebo over roughly 16 months of treatment. Because adipose tissue is a major site of aromatase activity, meaningful fat loss is expected to reduce total estrogen production and, with it, the total pool of urinary estrogen metabolites, while sex hormone-binding globulin (SHBG) commonly rises with weight loss, further lowering free estradiol. No published GLP-1 trial has reported a full urinary estrogen metabolite panel as a primary or secondary endpoint. Any specific percentage change in a metabolite or ratio attributed to semaglutide or tirzepatide should be treated as unverified until a dedicated study is identified, and clinicians should expect absolute metabolite concentrations to fall with significant fat mass loss while ratios may shift only modestly.

DIM and indole-3-carbinol

Diindolylmethane (DIM) and its precursor indole-3-carbinol (I3C) are dietary supplements, not FDA-approved drugs, and their manufacturing is not subject to the same quality controls as prescription medications. Small controlled studies have reported that DIM supplementation induces CYP1A2 activity and raises the 2-OHE1:16α-OHE1 ratio over several weeks. The clinical implication for testing is straightforward regardless of the exact magnitude reported in any one study: a favorable ratio on a panel does not reflect a person's baseline metabolic capacity if they have been taking DIM or I3C in the weeks before collection, and supplement use must be disclosed to the ordering clinician so a baseline can be distinguished from a treatment response.

Progesterone metabolites and delivery route

Oral micronized progesterone (for example, Prometrium) is FDA-approved and is metabolized to pregnanediol and, importantly, to allopregnanolone, a compound with GABAergic, anxiolytic, and sleep-promoting activity. Synthetic progestins such as medroxyprogesterone acetate (MPA) follow different metabolic pathways and do not generate allopregnanolone in the same way. This distinction is one reason clinicians increasingly treat oral micronized progesterone and synthetic progestins as pharmacologically distinct rather than interchangeable when discussing cardiovascular or breast cancer risk associated with combined hormone therapy, a distinction that professional society statements on menopausal hormone therapy have generally supported, though readers should confirm current wording directly with the issuing society rather than rely on a quoted excerpt, since the exact phrasing could not be verified against a checked primary source for this article. A woman on oral micronized progesterone with low urinary allopregnanolone despite adequate serum progesterone may have variable first-pass conversion to allopregnanolone; this is a plausible explanation for persistent insomnia or anxiety on progesterone therapy, worth raising with a prescriber, rather than an established diagnostic finding.

Androgen metabolites

Androsterone and etiocholanolone are downstream androgen metabolites tracked on comprehensive panels, and DHEA supplementation raises DHEA-S and, through aromatization, some estrogen metabolites as well. In men on testosterone therapy, unexpectedly low androsterone and etiocholanolone despite reported adherence should prompt questions about absorption (particularly with transdermal gel or patch formulations), injection technique, or missed doses, rather than an assumption that the underlying metabolic pathway itself has failed.

Pre-test variables that distort results

A result is only as good as the sample behind it.

• Creatinine normalization. Values should be reported per gram of creatinine to correct for urine dilution; confirm the lab report shows creatinine-adjusted values before comparing to any reference range.
• Cycle timing. In premenstrual women, progesterone metabolites vary substantially across the cycle; luteal-phase collection (commonly days 19 to 22 of a 28-day cycle) is the standard convention for progesterone metabolite interpretation. Estrogen ratios are comparatively more stable across the cycle but should still be compared collection-phase to collection-phase on repeat testing.
• Gut microbiome and antibiotics. Gut bacteria expressing beta-glucuronidase (sometimes called the estrobolome) can deconjugate estrogen metabolites and allow reabsorption; high fiber intake is thought to reduce this recirculation, and antibiotic use in the weeks before testing can meaningfully alter results in either direction. Recent antibiotic use should be disclosed when ordering the panel.
• Undisclosed supplements. DIM, I3C, and DHEA are common over-the-counter supplements that shift results and are frequently omitted from intake forms unless specifically asked about.

Ordering a panel that actually answers the clinical question

A serum estradiol test alone does not capture pathway information. A comprehensive urinary panel intended to inform metabolism questions should include 2-OHE1, 4-OHE1, and 16α-OHE1 (with ratio calculations), 2-MeOE1 to assess COMT activity, estriol where relevant, pregnanediol and allopregnanolone, androsterone, etiocholanolone, and DHEA-S, and creatinine for normalization. Commercial DUTCH panels and 24-hour urine steroid profiles from major reference laboratories both capture these analytes; neither has been adopted into routine endocrinology or oncology guideline-based screening as of this writing (dated 2025), and coverage and clinical acceptance vary by lab and by payer.

When to retest after a medication or supplement change

Enzyme induction or suppression generally needs time to reach a new steady state. A commonly used clinical convention is to retest 8 to 12 weeks after starting or stopping a relevant medication or supplement, allowing for hepatic enzyme changes to stabilize; retesting at 4 weeks risks underestimating the full effect of slower-acting agents, and retesting later than 16 weeks may be reasonable if diet was also changed at the same time. This is a practical convention drawn from general pharmacokinetic principles rather than a single validated trial specific to this panel, and clinicians should adjust it based on the specific drug's known half-life and induction kinetics.

Decision framework: what to check before trusting a ratio number

Use this sequence before acting on any urinary sex steroid metabolite result. It is designed to catch the most common interpretation errors described above.

Step 1 - Confirm what was actually measured. Was creatinine normalization applied? Was the collection timed correctly (luteal phase for progesterone questions, consistent timing for repeat estrogen comparisons)? If either is unclear, request clarification from the lab before interpreting anything else.

Step 2 - List every hormone, supplement, and antibiotic used in the prior 8 weeks. Oral versus transdermal estrogen, any aromatase inhibitor or SERM, testosterone in any form, DHEA, DIM or I3C, and any antibiotic course all change the expected baseline. A ratio interpreted without this list is not interpretable.

Step 3 - Match the medication to its expected direction of effect, not a universal target.

• On oral estrogen: expect a lower 2:16 ratio than the same person would show on transdermal estrogen; do not compare against an unmedicated reference range.
• On an aromatase inhibitor: expect very low absolute values across the board; interpret absolute concentrations, not the ratio.
• On DIM/I3C: expect an artificially favorable 2:16 ratio; this reflects supplement effect, not baseline metabolic capacity.
• On a GLP-1 agonist with significant weight loss: expect lower absolute metabolite concentrations and possibly modest ratio shifts; there is no validated metabolite-specific benchmark for this scenario.
• On testosterone therapy (any sex): expect estrogen metabolites to move with aromatization; assess body composition if 4-OHE1 specifically is elevated.

Step 4 - Decide whether the finding changes management or only needs disclosure. Most medication-driven shifts described above explain a number rather than indicate a new problem requiring intervention. A finding should only prompt a management change (dose adjustment, route change, additional testing) if it is unexplained by the current medication and supplement list, or if it accompanies a symptom the patient is actively trying to solve (unexplained insomnia with low allopregnanolone, for example).

Step 5 - Escalate outside routine interpretation when:

• A result is being used to justify stopping or starting cancer-related therapy (tamoxifen, aromatase inhibitors) without discussion with the prescribing oncologist.
• A patient reports new breast changes, abnormal bleeding, or other symptoms that warrant standard clinical evaluation; a urinary metabolite panel should never substitute for mammography, clinical breast exam, or a prescriber's standard workup for these symptoms.
• Values are being used to self-direct high-dose supplementation (DIM, I3C, DHEA) without clinician oversight, particularly in patients with a personal or strong family history of hormone-sensitive cancer.

A note on evidence and citations in this article

Several numeric findings that appeared in earlier drafts of this content, including specific relative-risk figures, percentage changes, and a quoted excerpt attributed to a professional society statement, could not be verified against a checked primary source during this review and have been removed or rewritten as hedged, directional statements. Where a reader or clinician needs an exact figure for a clinical decision, the underlying study should be located and read directly rather than relied upon secondhand. This article should be treated as background education, not as a substitute for a laboratory's own reference materials or a treating clinician's interpretation of an individual result. Anyone with symptoms suggestive of a hormone-sensitive cancer, abnormal bleeding, or unexplained breast changes should seek standard clinical evaluation rather than rely on a urinary metabolite panel for reassurance or diagnosis.